Brainberry UK has been awarded a £900,000 grant from Innovate UK, in partnership with the Manufacturing Technology Centre (MTC) and the University of Ulster.
This funding will support the development of advanced therapeutic AI models that leverage precision and personalised brainwave technology to detect early-stage dementia.
This significant grant will enable Brainberry UK, along with its esteemed partners, to push the boundaries of healthcare innovation. By integrating cutting-edge AI techniques with precision brainwave analysis, the team aims to revolutionise early detection methods for dementia, offering personalised approaches and improved outcomes for millions of individuals.
“We are honoured to receive this grant from Innovate UK and to collaborate with MTC and the University of Ulster,” said Kartheka Bojan, CEO of Brainberry UK. “This funding will accelerate our mission to develop AI models that can make a profound difference in the lives of individuals affected by dementia. Early detection is key, and our personalised brainwave technology represents a groundbreaking approach.”
The partnership between Brainberry UK, MTC, and the University of Ulster will focus on leveraging sophisticated AI algorithms to interpret brainwave data with precision, identifying early markers of dementia with unprecedented accuracy. This personalised approach ensures that the AI models are tailored to the unique neurological patterns of each individual, enhancing the effectiveness of early intervention strategies.
Article provided by Medilink Midlands Member Brainberry UK.
